MC
GILD icon

Moors & Cabot’s Gilead Sciences GILD Stock Holding History

Moors & Cabot’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-46,800
Closed -$30K – 647
2019
Q3 		$30K Buy
+46,800
New +$3.06M ﹤0.01% 624

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Moors & Cabot's GILD Position: Q1 2026 in Review

Moors & Cabot reduced its Gilead Sciences (GILD) stake by 8.5% in Q1 2026, selling an estimated $242K and leaving 18,681 shares worth $2.6M. The position accounts for 0.11% of the portfolio, ranked #171.

Moors & Cabot first reported a position in GILD in Q1 2014 and has held it in 49 quarters since. The position peaked at $3.25M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Moors & Cabot held 18,681 shares of Gilead Sciences worth $2.6M as of Q1 2026.
  • Moors & Cabot sold 1,726 Gilead Sciences shares in Q1 2026, an estimated $242K.
  • Gilead Sciences made up 0.11% of Moors & Cabot's portfolio in Q1 2026, its #171 holding.
  • Moors & Cabot first reported a position in Gilead Sciences in Q1 2014 and has held it in 49 quarters since.
  • Moors & Cabot's Gilead Sciences position peaked at $3.25M in Q2 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.